Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

ANRO vs EQ: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ANRO Captures Overall Composite Edge (34.1 SELL vs 48.0 HOLD), While EQ Leads 3–1 on Growth & Valuation Pillars

ANRO Overall Winner 6-Pillar Tally: ANRO 1 – 3 EQ (2 Tie) Matrix Metrics: ANRO 5 – 3 EQ

As of Nov 19, 2026, Alto Neuroscience Inc. (ANRO) captures the overall head-to-head institutional edge over Equillium, Inc. (EQ) on higher Unified Composite conviction (34.1/100 SELL vs. 48.0/100 HOLD) after splitting the core matrix 5–3 (led by Growth & Scale), while EQ wins 3–1 across the 6-pillar growth and valuation breakdown. ANRO trades at $26.51 (N/M Forward P/E, 0.0% operating margin) versus EQ at $1.12 (1.5x Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While EQ currently prints a higher short-term Unified Composite Score (48.0/100 HOLD vs. ANRO 34.1/100 SELL), ANRO captures the overall institutional head-to-head verdict (5–3 matrix metrics and 1–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. -52.3% YoY).
  • Technical & Structure Timing Caution: ANRO is currently in a Breakdown options structure phase (RSI 52.3); meanwhile EQ is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ANRO vs EQ
ANRO NYSE Head-to-Head Winner
Alto Neuroscience Inc.
Pharmaceutical Preparations
$26.51
+2.32% 1D
Market Cap $1.0B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.95β · 91% Vol
Unified Composite Score
34.1 / 100 SELL
Tech 15.0 Fund 38.0 Flow 65.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 52
RSI-14: 52.3 · SMA20: $25.20 · SMA50: $25.71
EQ NASDAQ
Equillium, Inc. Common Stock
Pharmaceutical Preparations
$1.12
+1.82% 1D
Market Cap $90.6M
TTM Revenue $4.4M
Forward P/E 1.5x
Beta / 30D Vol 1.53β · 93% Vol
Unified Composite Score
48.0 / 100 HOLD
Tech 30.0 Fund 51.0 Flow 63.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -20.8%), weak momentum, RSI 36
RSI-14: 36.0 · SMA20: $1.33 · SMA50: $1.49

6-Pillar Scorecard Institutional Category Breakdown (ANRO 1 – 3 EQ)

Columns: Metric · ANRO · EQ
1. Valuation Multiples EQ
Forward P/E N/M 1.5x
Trailing P/E N/M 1.5x
PEG Ratio N/M N/M
EV / Revenue N/M 7.7x
2. Growth & Scale ANRO
Revenue Growth (YoY) +0.0% -52.3%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $4.4M
Market Cap $1.0B $90.6M
3. Profitability & Quality Tie
Gross Margin N/A 100.0%
Operating Margin 0.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -46.7% -59.0%
4. Balance Sheet & Cash Flow EQ
Cash Generation (TTM) -$80M -$20M
Cash Flow Margin N/A N/A
Net Cash / Leverage $301M Net Cash $57M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning EQ
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 78.2% (8th %ile) 261.3% (100th %ile)
Put/Call OI Skew 21.00x (Put-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ANRO (5) vs EQ (3)
Institutional Metric ANRO EQ Criterion Row Edge
Market Capitalization
Scale
$1.0B $90.6M Larger Scale ANRO
Trailing P/E Ratio
Valuation
N/M 1.5x Lower Multiple EQ
Forward P/E Ratio
Valuation
N/M 1.5x Lower Multiple EQ
Revenue Growth (YoY)
Growth
+0.0% -52.3% Higher Growth ANRO
Operating Margin (TTM)
Profitability
0.0% 0.0% Higher Margin Tie
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-46.7% -59.0% Higher ROE ANRO
52-Week Range Position
Momentum
56% ($13–$37) 11% ($1–$4) Stronger Trend ANRO
Beta / 30D Volatility
Risk Regime
1.95β · 91% Vol 1.53β · 93% Vol Lower Realized Risk ANRO
Unified Institutional Score
Composite Signal
34.1 / 100 (SELL) 48.0 / 100 (HOLD) Higher Composite EQ
Trailing 12M Revenue (USD)
Operating Scale
N/A $4.4M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 100.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 7.7x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$80M ($301M Net Cash) -$20M ($57M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ANRO +34.81 pp
ANRO: +13.68% · EQ: -21.13%
3M Horizon ANRO +28.85 pp
ANRO: -22.67% · EQ: -51.52%
6M Horizon ANRO +72.39 pp
ANRO: +23.07% · EQ: -49.32%
1Y Horizon ANRO +67.73 pp
ANRO: +79.73% · EQ: +12.0%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ANRO vs EQ. Trailing 12-month operating profitability (ANRO 0.0% vs EQ 0.0%) and valuation multiples (ANRO N/M vs EQ 1.5x Forward P/E) are benchmarked directly in Pillar 4 below.

ANRO ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-46.7% · N/M
EQ ADR TTM Benchmark FX-Normalized USD
TTM Revenue$4.4M
Gross Margin100.0%
Op. Margin0.0%
ROE / Fwd P/E-59.0% · 1.5x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ANRO BREAKDOWN
60d in phase · OBV DISTRIBUTION
Current IV 78.2%
IV Percentile 8th %ile
Put/Call OI Skew 21.00x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact ANRO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
EQ UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 261.3%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact EQ Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ANRO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.0B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
EQ Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $90.6M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ANRO vs EQ Key Questions & Quantitative Answers

As of Nov 19, 2026, Alto Neuroscience Inc. (ANRO) captures the overall head-to-head institutional edge over Equillium, Inc. (EQ) on higher Unified Composite conviction (34.1/100 SELL vs. 48.0/100 HOLD) after splitting the core matrix 5–3 (led by Growth & Scale), while EQ wins 3–1 across the 6-pillar growth and valuation breakdown. ANRO trades at $26.51 (N/M Forward P/E, 0.0% operating margin) versus EQ at $1.12 (1.5x Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While EQ currently prints a higher short-term Unified Composite Score (48.0/100 HOLD vs. ANRO 34.1/100 SELL), ANRO captures the overall institutional head-to-head verdict (5–3 matrix metrics and 1–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. -52.3% YoY). Technical & Structure Timing Caution: ANRO is currently in a Breakdown options structure phase (RSI 52.3); meanwhile EQ is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ANRO leads the Growth & Scale pillar: ANRO posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with EQ at -52.3% YoY revenue growth and +0.0% YoY earnings growth on $4.4M TTM revenue (100.0% gross margin, 0.0% operating margin). On trailing 12-month operating scale, ANRO generates N/A in USD-normalized revenue versus $4.4M for EQ. In operating R&D and SG&A reinvestment, ANRO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for EQ.

EQ screens cheaper on headline valuation multiples. ANRO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas EQ trades at 1.5x Forward P/E, 1.5x Trailing P/E, N/M PEG, and 7.7x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ANRO (-46.7% ROE) versus EQ (-59.0% ROE) capital efficiency.

In options market volatility and institutional positioning, ANRO carries 78.2% implied volatility (8th %ile, Compressed (<25th %ile)), a 21.00x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.95β · 91% Vol realized risk). By comparison, EQ carries 261.3% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.53β · 93% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.